An observational study in Dermatitis, Atopic, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 99 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Regeneron Pharmaceuticals · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals — 1 open to participants now, 2 under way, none of them phase 3. Dermatitis, Atopic · Regeneron Pharmaceuticals.
Among the 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals, this one is one of 4 that started in 2018, is one of 5 observational ones, and was the 21st registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →1 of the 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals is open now, in 2 countries. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States, Belgium
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 10 · Phase 3 10 · Phase 4 2
First in 2011; this study’s year is marked. 4 started in 2018.
This study's enrollment of 858 is above the median of 150 across 283 observational studies indexed under Dermatitis, Atopic.
Median enrollment 194 across the 25 interventional studies, 581 across the 5 observational. Of the 27 that completed or were terminated, 18 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
1 of the studies in Dermatitis, Atopic by Regeneron Pharmaceuticals that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03428646Regeneron PharmaceuticalsStudy of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD) | 2027-03-30 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A long-term observational registry in patients with atopic dermatitis (AD) initiating treatment with DUPIXENT® (dupilumab)
This is a prospective observational study conducted to (1) characterize the patients who receive DUPIXENT® for AD in a real world setting with respect to their medical history, socio-demographic and disease characteristics, and prior and concomitant treatments of AD; (2) characterize real world use patterns of DUPIXENT® for AD (eg, most commonly used regimens by line of therapy, reason for initiation of new treatments, concomitant therapies, treatment durations and reasons for discontinuation and/or switching); (3) assess the long-term effectiveness of DUPIXENT® in AD patients in a real world setting; (4) assess comorbid atopic conditions, patterns of use and effects of treatment in comorbid atopic conditions in patients who receive DUPIXENT® for AD; and (5) collect safety data on study participants
The target population comprises adult and adolescent patients (male or female, ≥12 years old), who are initiating treatment with DUPIXENT® for AD according to the country-specific prescribing information.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dupixent 1 dose at Baseline required for eligibility; otherwise, no therapeutic intervention required during the course of the study. In addition to (or substituting for) DUPIXENT®, participants may receive marketed drugs as deemed necessary by their physicians for the treatment of AD or comorbid conditions.
Also known as: DUPIXENT®, REGN668
Registry Assessment: Baseline Characteristics
Medical history
Time frame: At baseline (day when DUPIXENT treatment is initiated)
Registry Assessment: Baseline Characteristic
Socio-demographics
Time frame: At baseline (day when DUPIXENT treatment is initiated)
Registry (Physician) Assessment: Body Surface Area Affected (BSA) by Atopic Dermatitis
Percentage of BSA affected by AD assessed for each major section of the body
Time frame: Baseline to month 60
Registry (Physician) Assessment: Eczema Area and Severity Index (EASI)
Measure used in clinical practice and clinical trials to assess the severity and extent of AD
Time frame: Baseline to month 60
Registry (Physician) Assessment: Overall Disease Severity scale
Questionnaire used to characterizing the severity of AD on a 4-point scale (0=No disease, 1=Minimal disease, 2=Mild disease, 3=Moderate disease, 4=Severe disease)
Time frame: Baseline to month 60
Registry (Participant) Assessment: Patient Oriented Eczema Measure
Questionnaire used in clinical practice and clinical trials to assess disease symptoms in children and adults
Time frame: Baseline to month 60
Registry (Participant) Assessment: Pruritus Numerical Rating Scales (NRS)
Individual NRS used to rate the intensity of pruritus using a 0 to 10 numeric rating scale.
Time frame: Baseline to month 60
Registry (Participant) Assessment: Skin Pain or Soreness NRS
Individual NRS used to rate skin pain and soreness using a 0 to 10 NRS
Time frame: Baseline to month 60
Registry (Participant) Assessment: Skin Feeling Hot NRS
Individual NRS used to rate the sensation of skin feeling hot (burning sensation) using a 0 to 10 NRS
Time frame: Baseline to month 60
Registry (Participant) Assessment: Skin Sensitivity NRS
Individual NRS used to rate skin sensitivity using a 0 to 10 NRS
Time frame: Baseline to month 60
Registry (Participant) Assessment: Sleep Disturbance NRS
Individual NRS used to report the severity of their sleep disturbance using a 0 to 10 NRS
Time frame: Baseline to month 60
Registry (Participant) Assessment: Global Assessment of Atopic Dermatitis scale
Rate of overall well-being on a 5-point scale.
Time frame: Baseline to month 60
Registry (Participant) Assessment: Dermatology Life Quality Index (DLQI)
Questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life (QOL) in adults
Time frame: Baseline to month 60
Registry (Participant) Assessment: Children's Dermatology Life Quality Index (CDLQI)
Questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on QOL in pediatrics.
Time frame: Baseline to month 60
Registry (Participant) Assessment: Work Productivity and Activity Impairment Questionnaire for AD (WPAI-AD)
Questionnaire to assess the impact of AD on productivity.
Time frame: Baseline to month 60
Registry (Participant) Assessment: Health Care Resource Utilization Questionnaire
Questionnaire regarding hospitalization, or emergency room/ urgent care center visits due to AD.
Time frame: Baseline to month 60
Registry (Participant) Assessment: Dermatitis Family Impact Questionnaire
Questionnaire to assess the impact of atopic eczema on the QOL of the parents and family members of affected children.
Time frame: Baseline to month 60
Registry (Participant) Assessment: Missed School Days
Questionnaire to assess the number of missed school days since the last study assessment of adolescent patients (aged ≥ 12 to \< 18 years) who are enrolled in school.
Time frame: Baseline to month 60
Registry (Participant) Assessment: Juniper Asthma Control Questionnaire (ACQ-5)
5-question version of questionnaire to evaluate asthma control in registry patients with comorbid asthma.
Time frame: Baseline to month 60
Registry (Participant) Assessment: Allergic Rhinitis Visual Analog Scale (AR-VAS)
Questionnaire used as a validated measuring instrument for the documentation of symptoms and therapy monitoring in AR.
Time frame: Baseline to month 60
Registry (Participant) Assessment: Changes in Concurrent Conditions
Rate of change in any other condition(s) (other than eczema, asthma, and allergic symptoms) on a 2-point scale (Better or Worse).
Time frame: Baseline to month 60
Registry (Participant) Assessment: Overall Health State
Rate of overall state of health on a 5-point scale (Poor, Fair, Good, Very Good or Excellent).
Time frame: Baseline to month 60
Started Apr 2018 (actual). Primary completion is estimated for Mar 2027, 107 months after the start.
Of 74 industry-sponsored observational studies under Dermatitis, Atopic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 84. This study's planned 107 months is above that.
Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 17.
Completion moved once since we started tracking on Sep 25, 2026: Mar 2027 → Jul 2027, on Oct 9, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.